{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF59+adjuvant&page=2", "query": { "intervention": "MF59 adjuvant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF59+adjuvant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T11:04:10.319Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00133471", "title": "Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Influenza A/H9N2 vaccine", "type": "BIOLOGICAL" }, { "name": "MF59 adjuvant", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "34 Years", "sex": "ALL", "summary": "18 Years to 34 Years" }, "enrollment_count": 96, "start_date": "2005-03", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00133471" }, { "nct_id": "NCT00500747", "title": "Chiron Corp HCV E1/E2 Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "HCV E1E2/MF59", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 60, "start_date": "2003-08", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2011-06-10", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00500747" }, { "nct_id": "NCT02251288", "title": "A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Avian Influenza", "Immunisation" ], "interventions": [ { "name": "Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca", "type": "BIOLOGICAL" }, { "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013", "type": "BIOLOGICAL" }, { "name": "MF59 adjuvant", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "47 Years", "sex": "ALL", "summary": "18 Years to 47 Years" }, "enrollment_count": 62, "start_date": "2015-05-18", "completion_date": "2018-08-17", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02251288" }, { "nct_id": "NCT01942265", "title": "H7N9 Mix and Match With AS03 and MF59 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "AS03", "type": "DRUG" }, { "name": "MF59", "type": "DRUG" }, { "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 980, "start_date": "2013-09", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 5, "location_summary": "Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01942265" }, { "nct_id": "NCT02624219", "title": "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Avian Influenza", "Influenza" ], "interventions": [ { "name": "AS03", "type": "DRUG" }, { "name": "MF59 adjuvant", "type": "DRUG" }, { "name": "Monovalent Influenza A/H5N8 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 276, "start_date": "2016-08-16", "completion_date": "2018-01-30", "has_results": false, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 4, "location_summary": "Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02624219" }, { "nct_id": "NCT00073216", "title": "Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Clade B gag DNA/PLG and env DNA/PLG Microparticles", "type": "BIOLOGICAL" }, { "name": "Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 96, "start_date": null, "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 4, "location_summary": "St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073216" }, { "nct_id": "NCT00280033", "title": "H5 Adult - Chiron Study of Bird Flu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "BIOLOGICAL" }, { "name": "Inactivated Influenza A/H5N1 Vaccine (Chiron)", "type": "BIOLOGICAL" }, { "name": "MF-59", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 394, "start_date": "2006-02", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-09-13", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 4, "location_summary": "Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00280033" }, { "nct_id": "NCT03497845", "title": "Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza A Virus, H5N1 Subtype" ], "interventions": [ { "name": "VN", "type": "BIOLOGICAL" }, { "name": "IN", "type": "BIOLOGICAL" }, { "name": "dk/BANG", "type": "BIOLOGICAL" }, { "name": "gf/WA", "type": "BIOLOGICAL" }, { "name": "bhg/QL", "type": "BIOLOGICAL" }, { "name": "AS03 adjuvant", "type": "BIOLOGICAL" }, { "name": "MF59 adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biomedical Advanced Research and Development Authority", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 720, "start_date": "2018-03-15", "completion_date": "2019-11-19", "has_results": true, "last_update_posted_date": "2020-07-14", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 6, "location_summary": "San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03497845" }, { "nct_id": "NCT04576702", "title": "Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza", "Human" ], "interventions": [ { "name": "Investigational aIIV4c", "type": "BIOLOGICAL" }, { "name": "IIV4c", "type": "BIOLOGICAL" }, { "name": "aIIV4", "type": "BIOLOGICAL" }, { "name": "RIV4", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seqirus", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 471, "start_date": "2020-10-08", "completion_date": "2021-05-24", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 21, "location_summary": "Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Oakland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04576702" }, { "nct_id": "NCT00973349", "title": "Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "MF59-eH1N1_f", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2719, "start_date": "2009-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-09-26T11:04:10.319Z", "location_count": 20, "location_summary": "Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Endwell", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00973349" } ] }